Structure Therapeutics (NASDAQ:GPCR) Shares Up 4.7% – Time to Buy?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) rose 4.7% on Monday . The stock traded as high as $22.35 and last traded at $22.74. Approximately 203,750 shares were traded during trading, a decline of 76% from the average daily volume of 848,640 shares. The stock had previously closed at $21.73.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on GPCR. HC Wainwright reduced their target price on Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Monday, May 12th. Citigroup assumed coverage on Structure Therapeutics in a research note on Friday, May 2nd. They issued a “buy” rating and a $60.00 price objective on the stock. JMP Securities restated a “market outperform” rating and issued a $89.00 target price on shares of Structure Therapeutics in a research note on Monday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a report on Monday. Finally, William Blair initiated coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They set an “outperform” rating on the stock. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $76.17.

Structure Therapeutics Stock Down 2.5%

The company has a market cap of $1.22 billion, a P/E ratio of -24.36 and a beta of -1.87. The business has a 50-day moving average price of $23.26 and a two-hundred day moving average price of $24.14.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). As a group, sell-side analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Institutional investors have recently modified their holdings of the stock. Zimmer Partners LP lifted its holdings in shares of Structure Therapeutics by 77.1% during the 1st quarter. Zimmer Partners LP now owns 100,776 shares of the company’s stock valued at $1,744,000 after purchasing an additional 43,876 shares in the last quarter. Vestal Point Capital LP boosted its holdings in shares of Structure Therapeutics by 3.7% in the first quarter. Vestal Point Capital LP now owns 1,788,990 shares of the company’s stock valued at $30,967,000 after buying an additional 63,990 shares during the period. Cubist Systematic Strategies LLC increased its position in shares of Structure Therapeutics by 3,326.0% during the first quarter. Cubist Systematic Strategies LLC now owns 54,816 shares of the company’s stock worth $949,000 after acquiring an additional 53,216 shares in the last quarter. Point72 Europe London LLP raised its holdings in shares of Structure Therapeutics by 188.7% during the first quarter. Point72 Europe London LLP now owns 90,697 shares of the company’s stock worth $1,570,000 after acquiring an additional 59,277 shares during the period. Finally, DAFNA Capital Management LLC raised its holdings in shares of Structure Therapeutics by 66.2% during the first quarter. DAFNA Capital Management LLC now owns 59,000 shares of the company’s stock worth $1,021,000 after acquiring an additional 23,500 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.